HomeAI · summaries
Storia in 4 fonti
Tango plans Phase 3 pancreatic cancer study after combo success
Tango Therapeutics reports 92% ORR from vopimetostat plus daraxonrasib combo in pancreatic cancer, plans Phase 3 study later this year.
Confronto fonti
4 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Tango data add to growing momentum for pancreatic cancer drugs
A combination involving Tango’s experimental therapy appeared to boost response rates in a small clinical trial well beyond what would be expected, sparking a share surge.
- ·
benzinga.com
Why Is Tango Therapeutics Stock Soaring Monday? - Tango Therapeutics (NASDAQ:TNGX)
Tango Therapeutics reports 90% 6-month PFS in pancreatic cancer trial. Read about the vopimetostat combo driving TNGX stock up.
